T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Suppose a cancer patient has been told that he would be free of cancer cells and return to his normal life; that would be the ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report) today and set a ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

A cancer immunotherapy that has been incredibly effective against blood cancers in recent years is chimeric antigen receptor ...

The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple ...